European generics firms, squeezed between innovators and payers, seek diversity
20 June 2011
Ian Schofield
Please Login to read the full article.
20 June 2011
Ian Schofield
Please Login to read the full article.
RELATED CONTENT
NEWS
- Focus on Almirall: partnering, new products and mature markets are key targets
- BMS and Sanofi mentioned in $1bn deal speculation over Biocon's oral insulin
- End of an era in antibiotic blockbusters as FDA approves Levaquin generics
- China must clean up act before it can join fully in global pharma, says KPMG report
